+

WO2007150074A3 - Compositions comprenant du naproxène nanoparticulaire et de l'hydrocodone à libération contrôlée - Google Patents

Compositions comprenant du naproxène nanoparticulaire et de l'hydrocodone à libération contrôlée Download PDF

Info

Publication number
WO2007150074A3
WO2007150074A3 PCT/US2007/072052 US2007072052W WO2007150074A3 WO 2007150074 A3 WO2007150074 A3 WO 2007150074A3 US 2007072052 W US2007072052 W US 2007072052W WO 2007150074 A3 WO2007150074 A3 WO 2007150074A3
Authority
WO
WIPO (PCT)
Prior art keywords
hydrocodone
compositions
composition
component
controlled release
Prior art date
Application number
PCT/US2007/072052
Other languages
English (en)
Other versions
WO2007150074A2 (fr
Inventor
Paul Stark
John Devane
Niall Fanning
Gary Liversidge
Scott Jenkins
Gurvinder Singh-Rekhi
Original Assignee
Elan Pharma Int Ltd
Paul Stark
John Devane
Niall Fanning
Gary Liversidge
Scott Jenkins
Gurvinder Singh-Rekhi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Elan Pharma Int Ltd, Paul Stark, John Devane, Niall Fanning, Gary Liversidge, Scott Jenkins, Gurvinder Singh-Rekhi filed Critical Elan Pharma Int Ltd
Priority to EP07799011A priority Critical patent/EP2032137A2/fr
Priority to JP2009516756A priority patent/JP2009541359A/ja
Priority to MX2008016223A priority patent/MX2008016223A/es
Priority to AU2007260821A priority patent/AU2007260821B2/en
Priority to BRPI0713447-9A priority patent/BRPI0713447A2/pt
Priority to CA002660649A priority patent/CA2660649A1/fr
Publication of WO2007150074A2 publication Critical patent/WO2007150074A2/fr
Publication of WO2007150074A3 publication Critical patent/WO2007150074A3/fr
Priority to IL196065A priority patent/IL196065A0/en
Priority to NO20090158A priority patent/NO20090158L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Pulmonology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne des compositions comprenant une composition de naproxène nanoparticulaire en combinaison avec une composition d'hydrocodone à libération modifiée multiparticulaire qui, lorsqu'elle est administrée à un patient, libère de l'hydrocone d'une manière bimodale ou multimodale. La composition à libération modifiée multiparticulaire comprend une première composante et au moins une autre composante, la première composante comprenant une première population de particules comprenant de l'hydrocone et l'autre ou les autres composante(s) comprenant une seconde population de particules comprenant de l'hydrocone, la combinaison des composantes se caractérisant par un profil de libération bimodale ou multimodale. L'invention concerne également une forme de dosage solide pour administration par voie orale comprenant une telle composition combinée.
PCT/US2007/072052 2006-06-23 2007-06-25 Compositions comprenant du naproxène nanoparticulaire et de l'hydrocodone à libération contrôlée WO2007150074A2 (fr)

Priority Applications (8)

Application Number Priority Date Filing Date Title
EP07799011A EP2032137A2 (fr) 2006-06-23 2007-06-25 Compositions comprenant du naproxène nanoparticulaire et de l'hydrocodone à libération contrôlée
JP2009516756A JP2009541359A (ja) 2006-06-23 2007-06-25 ナノ粒子状ナプロキセンおよび制御放出ヒドロコドンを含む組成物
MX2008016223A MX2008016223A (es) 2006-06-23 2007-06-25 Composiciones que comprenden naproxen nanoparticulado e hidrocodona de liberacion controlada.
AU2007260821A AU2007260821B2 (en) 2006-06-23 2007-06-25 Compositions comprising nanoparticulate naproxen and controlled release hydrocodone
BRPI0713447-9A BRPI0713447A2 (pt) 2006-06-23 2007-06-25 composição forma de dosagem oral sólida, e, método para o tratamento de dor
CA002660649A CA2660649A1 (fr) 2006-06-23 2007-06-25 Compositions comprenant du naproxene nanoparticulaire et de l'hydrocodone a liberation controlee
IL196065A IL196065A0 (en) 2006-06-23 2008-12-18 Compositions comrising nanoparticulate naproxen and controlled release hydrocodone
NO20090158A NO20090158L (no) 2006-06-23 2009-01-12 Sammensetning omfattende nanopartikulaer naproxen og kontrollert frigivelseshydrokarbon

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US81588506P 2006-06-23 2006-06-23
US60/815,885 2006-06-23

Publications (2)

Publication Number Publication Date
WO2007150074A2 WO2007150074A2 (fr) 2007-12-27
WO2007150074A3 true WO2007150074A3 (fr) 2008-04-10

Family

ID=38834446

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/072052 WO2007150074A2 (fr) 2006-06-23 2007-06-25 Compositions comprenant du naproxène nanoparticulaire et de l'hydrocodone à libération contrôlée

Country Status (12)

Country Link
EP (1) EP2032137A2 (fr)
JP (1) JP2009541359A (fr)
KR (1) KR20090024284A (fr)
CN (1) CN101484170A (fr)
AU (1) AU2007260821B2 (fr)
BR (1) BRPI0713447A2 (fr)
CA (1) CA2660649A1 (fr)
IL (1) IL196065A0 (fr)
MX (1) MX2008016223A (fr)
NO (1) NO20090158L (fr)
WO (1) WO2007150074A2 (fr)
ZA (1) ZA200810221B (fr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2957281A1 (fr) 2001-09-21 2015-12-23 Egalet Ltd. Systeme de liberation a base de polymere
US20040253310A1 (en) 2001-09-21 2004-12-16 Gina Fischer Morphine polymer release system
EP1610767B1 (fr) 2003-03-26 2011-01-19 Egalet A/S Systeme de liberation regulee de morphine
US8821928B2 (en) 2007-06-04 2014-09-02 Egalet Ltd. Controlled release pharmaceutical compositions for prolonged effect
US20090311335A1 (en) * 2008-06-12 2009-12-17 Scott Jenkins Combination of a triptan and an nsaid
CA2751667C (fr) 2009-02-06 2016-12-13 Egalet Ltd. Composition a liberation immediate resistant a une maltraitance par prise d'alcool
WO2010149169A2 (fr) 2009-06-24 2010-12-29 Egalet A/S Formulations à libération contrôlée
CA2822790C (fr) 2010-12-22 2018-11-20 Purdue Pharma L.P. Formes pharmaceutiques encapsulees, inviolables et a liberation controlee
PH12013501345A1 (en) 2010-12-23 2022-10-24 Purdue Pharma Lp Tamper resistant solid oral dosage forms
KR101794032B1 (ko) * 2011-09-21 2017-11-07 (주)바이오시네틱스 나노입자 제조방법
JP2015521988A (ja) 2012-07-06 2015-08-03 イガレット・リミテッド 制御放出用乱用防止性医薬組成物
JP6208261B2 (ja) 2013-02-05 2017-10-04 パーデュー、ファーマ、リミテッド、パートナーシップＰｕｒｄｕｅ Ｐｈａｒｍａ Ｌ．Ｐ． タンパリング抵抗性医薬製剤
US10751287B2 (en) 2013-03-15 2020-08-25 Purdue Pharma L.P. Tamper resistant pharmaceutical formulations
US9132096B1 (en) 2014-09-12 2015-09-15 Alkermes Pharma Ireland Limited Abuse resistant pharmaceutical compositions
EP3355865B8 (fr) 2015-09-29 2025-02-19 Merz Pharmaceuticals, LLC Compositions à libération prolongée de 4-aminopyridine
CN112500694B (zh) * 2020-12-04 2022-03-29 东莞威赢高尔夫用品有限公司 一种电子设备贴皮材料及其制备方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6165506A (en) * 1998-09-04 2000-12-26 Elan Pharma International Ltd. Solid dose form of nanoparticulate naproxen
US20030129237A1 (en) * 1998-11-02 2003-07-10 Devane John G. Multiparticulate modified release composition
US20050031691A1 (en) * 2002-09-11 2005-02-10 Elan Pharma International Ltd. Gel stabilized nanoparticulate active agent compositions

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6165506A (en) * 1998-09-04 2000-12-26 Elan Pharma International Ltd. Solid dose form of nanoparticulate naproxen
US20030129237A1 (en) * 1998-11-02 2003-07-10 Devane John G. Multiparticulate modified release composition
US20050031691A1 (en) * 2002-09-11 2005-02-10 Elan Pharma International Ltd. Gel stabilized nanoparticulate active agent compositions

Also Published As

Publication number Publication date
EP2032137A2 (fr) 2009-03-11
NO20090158L (no) 2009-03-20
KR20090024284A (ko) 2009-03-06
JP2009541359A (ja) 2009-11-26
MX2008016223A (es) 2009-01-19
WO2007150074A2 (fr) 2007-12-27
AU2007260821A1 (en) 2007-12-27
IL196065A0 (en) 2009-09-01
AU2007260821B2 (en) 2012-06-21
CA2660649A1 (fr) 2007-12-27
CN101484170A (zh) 2009-07-15
BRPI0713447A2 (pt) 2012-03-13
ZA200810221B (en) 2009-11-25

Similar Documents

Publication Publication Date Title
WO2007150074A3 (fr) Compositions comprenant du naproxène nanoparticulaire et de l'hydrocodone à libération contrôlée
WO2007150075A3 (fr) Compositions comprenant du meloxicam nanoparticulaire et de l'hydrocodone à libération contrôlée
WO2006102610A3 (fr) Composes bicycloheteroaryle utilises en tant que modulateurs de p2x7 et leurs utilisations
WO2007109192A3 (fr) Composés de bicyclohétéroaryle en tant que modulateurs de p2x7 et leurs utilisations
WO2006131591A3 (fr) Forme posologique destinee a etre administree par voie orale
WO2007109172A3 (fr) Composés de bicyclohétéroaryle en tant que modulateurs de p2x7 et leurs utilisations
WO2008033351A3 (fr) Formulations multimode de libération prolongée et résistantes à l'abus
WO2007109160A3 (fr) Composés de bicyclohétéroaryle en tant que modulateurs de p2x7 et leurs utilisations
WO2007109154A3 (fr) Composés de bicyclohétéroaryle en tant que modulateurs de p2x7 modulators et leurs utilisations
IL195488A (en) Compounds, pharmaceuticals containing them and their uses
WO2007042271A3 (fr) Nouvelle utilisation de compositions nutraceutiques
IL196426A (en) Micro-particles based on amphiphilic copolymer, their preparation processes and their pharmaceutical preparations
WO2011106416A3 (fr) Formulations à l'épreuve d'un usage abusif
IL197831A (en) Human antibodies that bind 4cxcr, preparations containing them and their uses
WO2006099514A3 (fr) Composition d'administration de medicaments contenant un polymere et un agent modificateur
IL192967A0 (en) Vitamin e succinate stabilized pharmaceutical compositions, methods for the preparation and the use thereof
WO2010019239A3 (fr) Composition pharmaceutique et administrations de celle-ci
WO2008033911A3 (fr) Compositions dentaires incluant des organogélateurs, produits, et procédés
PT2029480T (pt) Nanopartículas biologicamente ativas de uma hidroxiapatite substituída por carbonato, processo para a sua preparação e composições que as incorporam
WO2007092755A3 (fr) Traitement de l'insuffisance et de la deficience de vitamine d avec de la 25-hydroxyvitamine d2 et de la 25-hydroxyvitamine d3
WO2007109182A3 (fr) Composés de bicyclohétéroaryle en tant que modulateurs de p2x7 et leurs utilisations
WO2007109201A3 (fr) Composés de bicyclohétéroaryle en tant que modulateur de p2x7 et leurs utilisations
WO2009087634A3 (fr) Méthodes et compositions pour l'administration orale d'insuline
MY144857A (en) Phamaceutical composition comprising amlodipine and losartan
WO2007002823A3 (fr) Formulations d'oestrogenes conjugues et de bazedoxifene

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200780023616.9

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07799011

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2007260821

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2660649

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2007799011

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: MX/A/2008/016223

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 196065

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2009516756

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2007260821

Country of ref document: AU

Date of ref document: 20070625

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1020097001439

Country of ref document: KR

NENP Non-entry into the national phase

Ref country code: RU

ENP Entry into the national phase

Ref document number: PI0713447

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20081222

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载